Analysts expect that Insulet Co. (NASDAQ:PODD) will post $197.63 million in sales for the current quarter, according to Zacks. Seven analysts have provided estimates for Insulet’s earnings, with the lowest sales estimate coming in at $197.00 million and the highest estimate coming in at $198.61 million. Insulet reported sales of $164.91 million in the same quarter last year, which would suggest a positive year over year growth rate of 19.8%. The company is scheduled to issue its next quarterly earnings results on Monday, February 24th.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
According to Zacks, analysts expect that Insulet will report full year sales of $726.66 million for the current financial year, with estimates ranging from $725.80 million to $728.21 million. For the next year, analysts forecast that the business will post sales of $856.62 million, with estimates ranging from $792.42 million to $885.60 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Insulet.
Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.02). Insulet had a return on equity of 9.46% and a net margin of 2.38%. The firm had revenue of $192.12 million during the quarter, compared to the consensus estimate of $179.50 million. During the same period in the previous year, the company posted $0.03 earnings per share. The company’s revenue for the quarter was up 27.2% on a year-over-year basis.
Several research firms recently commented on PODD. Canaccord Genuity downgraded shares of Insulet from a “buy” rating to a “hold” rating and raised their price objective for the stock from $135.00 to $145.00 in a report on Friday, October 18th. Jefferies Financial Group increased their target price on shares of Insulet from $105.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, August 6th. ValuEngine cut shares of Insulet from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Stifel Nicolaus began coverage on shares of Insulet in a research note on Tuesday, October 22nd. They issued a “hold” rating and a $163.00 target price on the stock. Finally, Raymond James increased their target price on shares of Insulet from $135.00 to $158.00 and gave the stock an “outperform” rating in a research note on Wednesday. Ten research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $151.71.
PODD stock traded up $4.59 during trading on Thursday, reaching $169.46. The stock had a trading volume of 1,241,100 shares, compared to its average volume of 751,627. The company’s 50 day moving average is $154.75 and its two-hundred day moving average is $130.77. The company has a market capitalization of $8.73 billion, a price-to-earnings ratio of 3,389.20 and a beta of 0.96. Insulet has a one year low of $70.80 and a one year high of $171.96. The company has a quick ratio of 3.91, a current ratio of 4.72 and a debt-to-equity ratio of 2.43.
In other news, SVP Michael P. Spears sold 4,153 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.12, for a total transaction of $606,836.36. Following the sale, the senior vice president now owns 22,626 shares in the company, valued at approximately $3,306,111.12. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Shacey Petrovic sold 649 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $152.40, for a total transaction of $98,907.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,491 shares of company stock worth $806,124. Corporate insiders own 3.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of PODD. Advisors Preferred LLC purchased a new stake in shares of Insulet during the 2nd quarter valued at $38,000. Harvest Fund Management Co. Ltd purchased a new position in Insulet in the 2nd quarter worth $43,000. Mitsubishi UFJ Securities Holdings Co. Ltd. purchased a new position in Insulet in the 2nd quarter worth $97,000. Steward Partners Investment Advisory LLC purchased a new position in Insulet in the 2nd quarter worth $119,000. Finally, Cerebellum GP LLC purchased a new position in Insulet in the 3rd quarter worth $122,000.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
See Also: High-Yield Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com